Tags

Type your tag names separated by a space and hit enter

Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.
Intern Med. 2020; 59(9):1227-1230.IM

Abstract

Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option.

Links

PMC Free PDF

Authors+Show Affiliations

Kosaka A
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.
Sakamoto N
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.
Hikone M
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.
Imai K
Department of Infectious Diseases and Infection Control, Saitama Medical University, Japan. Center for Clinical Infectious Diseases and Research, Saitama Medical University, Japan.
Ota M
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.
Washino T
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.
Maeda T
Department of Microbiology, Saitama Medical University, Japan.
Iwabuchi S
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

MeSH

Amphotericin BAntiprotozoal AgentsDiagnosis, DifferentialDose-Response Relationship, DrugHumansLeishmania braziliensisLeishmaniasis, CutaneousMaleMiddle AgedRetreatmentTreatment Failure

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

32378656

Citation

Kosaka, Atsushi, et al. "Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis Due to Leishmania Braziliensis." Internal Medicine (Tokyo, Japan), vol. 59, no. 9, 2020, pp. 1227-1230.
Kosaka A, Sakamoto N, Hikone M, et al. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. Intern Med. 2020;59(9):1227-1230.
Kosaka, A., Sakamoto, N., Hikone, M., Imai, K., Ota, M., Washino, T., Maeda, T., & Iwabuchi, S. (2020). Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. Internal Medicine (Tokyo, Japan), 59(9), 1227-1230. https://doi.org/10.2169/internalmedicine.4096-19
Kosaka A, et al. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis Due to Leishmania Braziliensis. Intern Med. 2020;59(9):1227-1230. PubMed PMID: 32378656.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. AU - Kosaka,Atsushi, AU - Sakamoto,Naoya, AU - Hikone,Mayu, AU - Imai,Kazuo, AU - Ota,Masayuki, AU - Washino,Takuya, AU - Maeda,Takuya, AU - Iwabuchi,Sentarou, Y1 - 2020/05/01/ PY - 2020/5/8/entrez PY - 2020/5/8/pubmed PY - 2020/7/31/medline KW - Leishmania braziliensis KW - cutaneous leishmaniasis KW - liposomal-amphotericin B SP - 1227 EP - 1230 JF - Internal medicine (Tokyo, Japan) JO - Intern Med VL - 59 IS - 9 N2 - Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option. SN - 1349-7235 UR - https://www.unboundmedicine.com/medline/citation/32378656/Failure_of_Liposomal_amphotericin_B_Treatment_for_New_World_Cutaneous_Leishmaniasis_due_to_Leishmania_braziliensis_ DB - PRIME DP - Unbound Medicine ER -